Open AccessP554: GILTERITINIB VERSUS SALVAGE CHEMOTHERAPY FOR RELAPSED/REFRACTORY FLT3‐MUTATED ACUTE MYELOID LEUKEMIA: A PHASE 3, RANDOMIZED, MULTICENTER, OPEN‐LABEL TRIAL IN ASIA
Author(s) -
Wang J.,
Jiang B.,
Li J.,
Liu L.,
Du X.,
Jiang H.,
Hu J.,
Yuan M.,
Sakatani T.,
Kadokura T.,
Takeuchi M.,
Izuka S.,
Girshova L.,
Tan J.,
Bondarenko S.,
Wong L. L. L.,
Khuhapinant A.,
Martynova E.,
Hasabou N.,
Tiu R.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845104.07004.2e
Subject(s) - medicine , tolerability , cytarabine , fludarabine , clinical endpoint , surgery , mitoxantrone , population , hazard ratio , myeloid leukemia , interim analysis , salvage therapy , gastroenterology , chemotherapy , randomized controlled trial , adverse effect , cyclophosphamide , confidence interval , environmental health